Symptomatic Therapy Trials

1. Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer

ClinicalTrials.gov Identifier: NCT01885754

Patients with lung cancer are more likely to experience cachexia, a severe debilitating disorder causing fatigue, weight loss, muscle wasting and associated with reduced physical function, increased chemotherapy toxicity and reduced survival. The study will explore muscle function, signaling pathways and its relationship to impaired functional capacity of patients with non-small-cell lung cancer (NSCLC); depending if whether they have cachexic state at diagnosis.
Quebec
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City

2. Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis (BAT-SCAN)

ClinicalTrials.gov Identifier: NCT01887769

This is a retrospective study extending over a period of 3 years conducted at the Institut universitaire de cardiologie et de pneumologie de Qu├ębec (2009-2012)., which aims to analyze body composition of patients with lung cancer at diagnosis using computed tomography (CT-Scan) image analysis.
PROV
CITY

Quebec
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City

3. Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer (TIDAL)

ClinicalTrials.gov Identifier: NCT01172925

The feeling of shortness of breath is very common in lung cancer. It is uncomfortable for patients and upsetting for their family. Although drugs like morphine and oxygen can help some patients feel better, they don't help everybody, and they are not used in patients with early symptoms. More relief is needed for these patients. The investigators are studying a drug called tiotropium, which is used in emphysema. It is an inhaler that opens the airways to allow easier breathing. Every patient will get the drug but also a placebo, in a random (flip of a coin) order. They will get each for 2 weeks. The investigators will see if they feel better with the drug.
Ontario
Juravinski Cancer Center, Hamilton

4. A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

ClinicalTrials.gov Identifier: NCT02080078

This study is to determine the use of theophylline in patients with NSCLC and advanced solid malignancies and whether treatment with theophylline will help lower or diminish the side effect of diarrhea in patients taking erlotinib. Patients will be enrolled in one of two parts of the study to verify the lowest dose of theophylline that is effective and the highest dose of erlotinib that can be tolerated with theophylline. If this study shows that theophylline is able to inhibit erlotinib induced diarrhea, it will help demonstrate that patients using the tyrosine kinase inhibitor (TKIs), erlotinib, can use it effectively at higher doses without experiencing severe diarrhea.
Alberta
Cross Cancer Institute, Edmonton

5. Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality (AMPLCaRe): A Randomized Placebo Controlled Clinical Trial

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00668707

There is evidence to support the use of melatonin, a natural health product, as an additional treatment aid for cancer patients. This study is designed to see if the daily ingestion of 20 milligrams of melatonin for one year can lower the incidence of developing lung cancer recurrence and/or death. Only patients with a diagnosis of non small cell lung cancer who are eligible for surgical resection can participate in the trial. The study will also be assessing for changes in quality of life, pain, fatigue, anxiety, sleep, and depression amongst the participants.
Ontario
London Health Sciences Center, London
Ottawa General Hospital, Ottawa
McMaster University, Hamilton
University Health Network, Toronto

Nova Scotia
QEII Health Sciences Centre/Capital Health, Halifax

British Columbia
Kelowna General Hospital, Kelowna
Fraser Health, Surrey

Quebec
Institut universitaire de cardiologie et de pneumologie de Quebec, Quebec City

6. Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

ClinicalTrials.gov Identifier: NCT00858364

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.
Ontario
Oshawa
Toronto

New Brunswick
Moncton

Quebec
Montreal
Sainte Jerome

7. A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01585883

The purpose of this study is to investigate the suitability and practicality of a coaching and support intervention in helping patients to use daily strategies for managing breathlessness. Also, the investigators will try to understand how useful it is in helping patients to reduce intensity of breathlessness and its impact their quality of life.
Ontario
Princess Margaret Hospital, Toronto

8. A Feasibility Study of Chinese Herbs to Manage Cancer related Symptoms in Patients With Advanced NSCLC (CH)

ClinicalTrials.gov Identifier: NCT02331394

The current proposal is a feasibility and acceptability study to establish the necessary groundwork for more detailed investigations into the role of CH in reducing symptoms and improving quality of life in NSCLC patients at the Jewish General Hospital (JGH). A standardized and easily administered form of CH will be used, incorporating a carefully selected combination of herbs designed to alleviate a range of common symptoms suffered by patients with advanced NSCLC.
Quebec
Jewish General Hospital, Montreal

9. An Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (CURCUMIN)

ClinicalTrials.gov Identifier: NCT02321293

The purpose of this study is to assess the safety and tolerability of curcumin in combination with EGFR-TKIs in selected patients with advanced non-resectable mutant EGFR NSCLC.
Quebec
Jewish General Hospital, Montreal

10. Incentive Spirometry Added to Physiotherapy to Reduce Postoperative Pulmonary Complications After Lung Surgery

ClinicalTrials.gov Identifier: NCT02146092

After any surgery, there is a chance of complications. After lung surgery to remove tumours, there is a particularly high chance of a person developing an infection or needing help breathing, called post-operative pulmonary complications. Currently, the risk of these complications is reduced through the completion of light physical and deep breathing exercises and walking around as soon as possible after surgery. Another possible way of helping these patients is to use a small device called an Incentive Spirometer to encourage and measure deep breathing. This study wants to compare how often postoperative pulmonary complications happen after major lung surgery between a group completing the exercises alone and a group using the Incentive spirometer in addition to the exercises. It is hoped that the combined therapy will reduce the amount of time patient must stay in hospital, have fewer complication events and have fewer patients re-admitted back into the hospital after they go home, so that patients overall have better outcomes.
Ontario
St Joseph’s Healthcare, Hamilton

11. Multimodal Prehabilitation to Enhance Functional Recovery After Lung Surgery

ClinicalTrials.gov Identifier: NCT02938104

The investigators propose a randomized controlled study in patients undergoing lung resection for cancer to compare the impact of multimodal intervention composed of exercise, nutritional supplement and psychological well-being on functional exercise capacity. One group (rehabilitation group) will receive the multimodal intervention after surgery for 8 weeks; the other will start 4 weeks before surgery and continue for 8 weeks postop (pre-rehabilitation group). In this case, both groups will be exposed to the program, which will be available to both groups postoperatively. One of the two groups will start this program 4 weeks before surgery and continue for 8 weeks postoperatively, and the other will start once they leave the hospital and continue for 8 weeks post-operatively.
Quebec
Montreal General Hospital, Montreal